“Some people will have this big burst of openness, and they won’t have the support to deal with it,” she says. Therefore, new startups offering psychedelic treatment without the assisted therapy component could stand to actually do harm, Watts worries. Afterward, participants received aftercare, known as “integration,” in which they process everything that happened during the trip.
“The drug was a catalyst to the therapeutic process, not the therapeutic process itself,” she wrote in her Medium piece when describing her involvement in the Imperial trial. The media leapt at it and startups sprung up, followed by obsessive patenting of psychedelic compounds. Then in 2018, the US Food and Drug Administration granted psilocybin “breakthrough therapy” status for depression, which gives a treatment the fastest possible route to approval. The pattern has gone something like this: Forbidden for decades, psychedelics began to reemerge in recent years out of fringe underground communities and into labs as potential revolutionary treatments for mental illnesses. But I think it’s a really important message to get out.” To trace psychedelics’ potential future, Yaden, Griffiths, and Potash looked to a model called the Gartner Hype Cycle, which can be used to characterize the trend cycle of new technologies, like virtual reality or 4D printing. “I think there’s a real reason for excitement. “I don’t want to be a wet blanket,” Yaden says. In a new opinion piece published in the Journal of the American Medical Association, Yaden-with his coauthors Roland Griffiths and James Potash, two experts in psychedelics and psychiatry, respectively-argues that if we don’t tread carefully, psychedelic research could end up back where it started: treated with deep suspicion, if not completely outlawed. “Now all of a sudden, within the past year or so, the pendulum has swung all the other way,” says David Yaden, an assistant professor at the Johns Hopkins University School of Medicine who studies the subjective effects of psychedelics.īut Yaden thinks the field is in danger of overcorrecting. At the same time, legislation and stigma surrounding psychedelics has slowly begun to loosen in recent years, and it increasingly looks like it might shake loose altogether. We’re firmly in the midst of a psychedelic renaissance, with substances long regarded simply as recreational drugs-such as psilocybin, LSD, and MDMA-being reappraised as potential treatments for a number of mental health conditions.
0 kommentar(er)
